Viscient Bio

Viscient Bio Inc.Founded in 2017 and headquartered in San Diego, US, Viscient Bio Inc. focuses on developing sophisticated human tissue models, including a liver model that accurately mimics fatty liver disease. The company was co-founded by Jeffrey Miner and Keith Murphy, with Keith Murphy serving as CEO.Viscient Biosciences specializes in advanced biotechnology, particularly through its innovative 3D tissue technology. The company’s core product offerings include sophisticated human tissue models, specifically its liver model, which has garnered recognition for accurately representing the characteristics of fatty liver disease. These models are designed to replace traditional animal testing, providing more relevant data for drug development while showcasing known disease patterns through microscopy and gene expression analysis. The primary end users of these products are pharmaceutical companies and research institutions engaged in drug development and safety testing.Viscient Biosciences generates revenue through business-to-business transactions with pharmaceutical and biotechnology companies, leveraging their proprietary 3D tissue models in drug development processes. The structure of transactions typically involves partnerships and collaborations, where clients may engage Viscient to utilize their liver model in preclinical studies. Revenue is expected to derive from service agreements and licensing arrangements related to drug candidates developed using Viscient’s technology. The company is actively advancing its drug development pipeline, with one drug already progressing to the preclinical stage and another set for Phase 2 studies, indicating a strategic focus on monetizing its technology through successful drug outcomes and associated collaborations.In June 2019, Viscient Bio Inc. It aims to launch new 3D tissue models in the coming years, improving the capabilities of its existing liver model and potentially introducing new models tailored to different disease states. Viscient is also looking to establish collaborations with additional pharmaceutical companies to broaden its reach and impact in drug development, indicating a strategic growth trajectory focused on innovation and market expansion.

1. Series A

   Jun 10, 2019

   Amount

   Undisclosed

   Investors

   Locked

2. Seed

   May 30, 2019

   Amount

   Undisclosed

   Investors

   Locked